GB8626412D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB8626412D0
GB8626412D0 GB868626412A GB8626412A GB8626412D0 GB 8626412 D0 GB8626412 D0 GB 8626412D0 GB 868626412 A GB868626412 A GB 868626412A GB 8626412 A GB8626412 A GB 8626412A GB 8626412 D0 GB8626412 D0 GB 8626412D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB868626412A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clark M R
WALDMANN H
Original Assignee
Clark M R
WALDMANN H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clark M R, WALDMANN H filed Critical Clark M R
Priority to GB868626412A priority Critical patent/GB8626412D0/en
Publication of GB8626412D0 publication Critical patent/GB8626412D0/en
Priority to GB8725811A priority patent/GB2197322B/en
Priority to PCT/GB1987/000781 priority patent/WO1988003565A1/en
Priority to EP19870907123 priority patent/EP0289546A1/en
Priority to JP50649787A priority patent/JPH01501200A/en
Priority to AU81569/87A priority patent/AU616871B2/en
Priority to DK348888A priority patent/DK348888A/en
Pending legal-status Critical Current

Links

GB868626412A 1986-11-05 1986-11-05 Antibodies Pending GB8626412D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB868626412A GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies
GB8725811A GB2197322B (en) 1986-11-05 1987-11-04 Antibodies
PCT/GB1987/000781 WO1988003565A1 (en) 1986-11-05 1987-11-04 Antibodies
EP19870907123 EP0289546A1 (en) 1986-11-05 1987-11-04 Antibodies
JP50649787A JPH01501200A (en) 1986-11-05 1987-11-04 antibody
AU81569/87A AU616871B2 (en) 1986-11-05 1987-11-04 Bi-specific antibodies having cytotoxic activities
DK348888A DK348888A (en) 1986-11-05 1988-06-24 ANTIBODIES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868626412A GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies

Publications (1)

Publication Number Publication Date
GB8626412D0 true GB8626412D0 (en) 1986-12-03

Family

ID=10606821

Family Applications (2)

Application Number Title Priority Date Filing Date
GB868626412A Pending GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies
GB8725811A Expired - Fee Related GB2197322B (en) 1986-11-05 1987-11-04 Antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB8725811A Expired - Fee Related GB2197322B (en) 1986-11-05 1987-11-04 Antibodies

Country Status (5)

Country Link
EP (1) EP0289546A1 (en)
JP (1) JPH01501200A (en)
AU (1) AU616871B2 (en)
GB (2) GB8626412D0 (en)
WO (1) WO1988003565A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
ES2073394T3 (en) * 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc BIFUNCTIONAL ANTIBODY CONSTRUCTS AND THEIR USE TO SELECTIVELY DESTROY CELLULAR POPULATIONS.
EP0308936B1 (en) * 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
EP0334300A1 (en) * 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
FI105320B (en) * 1988-04-04 2000-07-31 Oncogen Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2062795A1 (en) * 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE4419399C1 (en) * 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Process for the preparation of heterologous bispecific antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE218143T1 (en) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY
ES2169299T3 (en) 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt PROCEDURE FOR THE DESTRUCTION OF CONTAMINANT TUMOR CELLS IN MOTHER CELL TRANSPLANTS USING SPECIFIC ANTIBODIES.
AU2002323236A1 (en) 2001-08-17 2003-03-03 Gerlad Elfenbein In situ immunization
WO2003040341A2 (en) 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
BR0314629A (en) 2002-09-19 2005-08-02 Us Gov Health & Human Serv Polypeptides of p. ariasi polypeptides from p. perniciosus and methods and use
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2657443T3 (en) 2005-03-25 2018-03-05 Gitr, Inc. Anti-GITR antibodies and uses thereof
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
EP2441469A1 (en) 2006-03-14 2012-04-18 Oregon Health and Science University Methods for producing an immune response to tuberculosis
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP3124046B1 (en) 2007-07-12 2019-12-25 GITR, Inc. Combination therapies employing gitr binding molecules
EP2385371B1 (en) 2008-09-22 2014-10-22 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
WO2011063283A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
EP2591099B1 (en) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimeric clotting factors
PL2606064T3 (en) 2010-08-16 2015-07-31 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies
US9945842B2 (en) 2010-09-03 2018-04-17 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2709655B1 (en) 2011-05-17 2018-11-14 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
EP2524699A1 (en) 2011-05-17 2012-11-21 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
SI3572517T1 (en) 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US20140234307A1 (en) 2011-09-27 2014-08-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
MX350378B (en) 2012-01-10 2017-09-05 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier.
WO2013152352A1 (en) 2012-04-06 2013-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Live, attenuated rubella vector to express vaccine antigens
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
DK2898329T3 (en) 2012-09-24 2017-07-17 Ventana Med Syst Inc PROCEDURE FOR IDENTIFYING TREATMENT RESPONSIBLE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC Lymphoma Kinase (ALK) AS MARKER
EP2939026B1 (en) 2012-12-28 2017-07-05 Ventana Medical Systems, Inc. Image analysis for breast cancer prognosis
WO2014164472A1 (en) 2013-03-10 2014-10-09 The Board Of Regents Of The University Of Texas System Biomarkers for chagas disease related cardiomyopathy
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015199976A1 (en) 2014-06-24 2015-12-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Target activated microdissection
AR101262A1 (en) 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
EP3177323B2 (en) 2014-08-08 2023-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
US11014088B2 (en) 2016-03-09 2021-05-25 The Board Of Regents Of The University Of Texas System Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
AU2018347796A1 (en) 2017-10-10 2020-05-07 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2024044687A1 (en) 2022-08-26 2024-02-29 Valo Health, Inc. Biomarker combinations for prognosis and management of diabetic retinopathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor

Also Published As

Publication number Publication date
EP0289546A1 (en) 1988-11-09
GB8725811D0 (en) 1987-12-09
GB2197322A (en) 1988-05-18
GB2197322B (en) 1990-10-10
AU616871B2 (en) 1991-11-14
AU8156987A (en) 1988-06-01
WO1988003565A1 (en) 1988-05-19
JPH01501200A (en) 1989-04-27

Similar Documents

Publication Publication Date Title
GB2197322B (en) Antibodies
GB2209757B (en) Altered antibodies
GB8408193D0 (en) Antibodies
GB2197323B (en) Antibodies
GB8608068D0 (en) Monoclonal antibodies
GB8614084D0 (en) Immunoassay
GB8624899D0 (en) Monoclonal antibodies
GB8621910D0 (en) Monoclonal antibodies
GB8505487D0 (en) Antibodies
GB8715347D0 (en) Monoclonal antibodies
GB8726230D0 (en) Antibodies
GB8616174D0 (en) Monoclonal antibodies
GB8629740D0 (en) Immunoassay
GB8710074D0 (en) Antibodies
GB8610203D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
GB8623088D0 (en) Antibodies
GB8620589D0 (en) Antibodies
GB8610318D0 (en) Antibodies
GB8619998D0 (en) Antibodies
GB8621240D0 (en) Antigens
GB2215725B (en) Monoclonal antibodies
GB8708648D0 (en) Antibodies
GB8729520D0 (en) Antibodies
GB8506372D0 (en) Antibodies